Lombard M, Bomford A, Hynes M, Naoumov N V, Roberts S, Crowe J, Williams R
Liver Unit, Kings College Hospital, London, United Kingdom.
Hepatology. 1989 Jan;9(1):1-5. doi: 10.1002/hep.1840090102.
The liver is the main site of iron accumulation and pathologic sequelae in hereditary hemochromatosis. Whether this is a result solely of inappropriately increased absorption of iron by the gastrointestinal tract or a more generalized regulatory failure of iron balance is unknown. Using immunohistochemical techniques, we have examined the effects of therapeutic changes in liver iron stores on the expression of the hepatic transferrin receptor in hereditary hemochromatosis. Ten patients with untreated hereditary hemochromatosis had no detectable staining for transferrin receptor in their liver biopsies. All had increased hepatic ferritin (mean = 19.9 micrograms per mg protein, range = 1 to 31.7 micrograms per mg protein) and hepatic iron levels (mean = 36.2 micrograms per mg protein, range = 3.6 to 69.9 micrograms per mg protein). In contrast, hepatocyte transferrin receptor was detected in seven patients in whom hepatic iron stores were markedly depleted by venesection (hepatic ferritin mean = 0.32 microgram per mg protein, range = 0.16 to 0.53 microgram per mg protein; hepatic iron mean = 0.98 microgram per mg protein, range = 0.3 to 2.1 micrograms per mg protein). Sequential data from one patient confirmed the reexpression of receptor in response to therapeutic iron depletion, whereas data from another patient studied during treatment illustrated a reciprocal relationship between liver tissue distribution of iron and expression of transferrin receptor. The finding that appropriate physiologic regulation of the hepatic transferrin receptor operates in hereditary hemochromatosis does not support the concept of a generalized defect in receptor-mediated uptake of transferrin-bound iron.
肝脏是遗传性血色素沉着症中铁蓄积和病理后遗症的主要部位。这仅仅是胃肠道铁吸收不当增加的结果,还是铁平衡更普遍的调节失败,目前尚不清楚。我们使用免疫组化技术,研究了遗传性血色素沉着症中肝脏铁储存的治疗性变化对肝转铁蛋白受体表达的影响。10例未经治疗的遗传性血色素沉着症患者的肝脏活检中未检测到转铁蛋白受体染色。所有患者的肝铁蛋白(平均=19.9微克/毫克蛋白,范围=1至31.7微克/毫克蛋白)和肝铁水平(平均=36.2微克/毫克蛋白,范围=3.6至69.9微克/毫克蛋白)均升高。相比之下,在7例通过放血使肝脏铁储存明显减少的患者中检测到肝细胞转铁蛋白受体(肝铁蛋白平均=0.32微克/毫克蛋白,范围=0.16至0.53微克/毫克蛋白;肝铁平均=0.98微克/毫克蛋白,范围=0.3至2.1微克/毫克蛋白)。一名患者的连续数据证实了受体在治疗性铁耗竭后重新表达,而另一名患者在治疗期间的研究数据表明肝脏组织中铁的分布与转铁蛋白受体的表达呈反比关系。遗传性血色素沉着症中肝转铁蛋白受体存在适当的生理调节这一发现不支持转铁蛋白结合铁的受体介导摄取存在普遍缺陷的概念。